Form 144 Filer Information UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF...
FORM 4 ☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b...
0001802768December 312023Q1FALSEhttp://fasb.org/us-gaap/2022#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherAssetsCurrenthttp://fasb.org/us...
Net cash provided by operating activities (GAAP) of $1,034 million and Adjusted Cash Receipts(1) (non-GAAP) of...
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it is...
DEF 14Afalse000180276800018027682022-01-012022-12-3100018027682020-01-012020-12-3100018027682021-01-012021-12-31...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to...
NEW YORK, April 17, 2023 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has...
NEW YORK, April 13, 2023 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will...
NY false 0001802768 --12-31 0001802768 2023-03-24 2023-03-24 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C...
Royalty Pharma’s founder and Chief Executive Officer, Pablo Legorreta, has also indicated that he intends to...
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and...
Royalty Pharma has acquired an interest in PureTech’s royalty in Karuna Therapeutics’ KarXT; Royalty Pharma and PureTech will share in royalties...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.